<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36522764</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>19</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1756-994X</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>15</Day></PubDate></JournalIssue><Title>Genome medicine</Title><ISOAbbreviation>Genome Med</ISOAbbreviation></Journal><ArticleTitle>Calculating variant penetrance from family history of disease and average family size in population-scale data.</ArticleTitle><Pagination><StartPage>141</StartPage><MedlinePgn>141</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">141</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13073-022-01142-7</ELocationID><Abstract><AbstractText Label="BACKGROUND">Genetic penetrance is the probability of a phenotype when harbouring a particular pathogenic variant. Accurate penetrance estimates are important across biomedical fields including genetic counselling, disease research, and gene therapy. However, existing approaches for penetrance estimation require, for instance, large family pedigrees or availability of large databases of people affected and not affected by a disease.</AbstractText><AbstractText Label="METHODS">We present a method for penetrance estimation in autosomal dominant phenotypes. It examines the distribution of a variant among people affected (cases) and unaffected (controls) by a phenotype within population-scale data and can be operated using cases only by considering family disease history. It is validated through simulation studies and candidate variant-disease case studies.</AbstractText><AbstractText Label="RESULTS">Our method yields penetrance estimates which align with those obtained via existing approaches in the Parkinson's disease LRRK2 gene and pulmonary arterial hypertension BMPR2 gene case studies. In the amyotrophic lateral sclerosis case studies, examining penetrance for variants in the SOD1 and C9orf72 genes, we make novel penetrance estimates which correspond closely to understanding of the disease.</AbstractText><AbstractText Label="CONCLUSIONS">The present approach broadens the spectrum of traits for which reliable penetrance estimates can be obtained. It has substantial utility for facilitating the characterisation of disease risks associated with rare variants with an autosomal dominant inheritance pattern. The yielded estimates avoid any kinship-specific effects and can circumvent ascertainment biases common when sampling rare variants among control populations.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Spargo</LastName><ForeName>Thomas P</ForeName><Initials>TP</Initials><Identifier Source="ORCID">0000-0003-4297-6418</Identifier><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, London, SE5 9RX, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Opie-Martin</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-0951-8589</Identifier><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, London, SE5 9RX, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bowles</LastName><ForeName>Harry</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-4072-5255</Identifier><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, London, SE5 9RX, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>Cathryn M</ForeName><Initials>CM</Initials><Identifier Source="ORCID">0000-0002-8249-8476</Identifier><AffiliationInfo><Affiliation>Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology &amp; Neuroscience, King's College London, de Crespigny Park, London, SE5 8AF, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical and Molecular Genetics, Faculty of Life Sciences and Medicine, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iacoangeli</LastName><ForeName>Alfredo</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-5280-5017</Identifier><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, London, SE5 9RX, UK. alfredo.iacoangeli@kcl.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics and Health Informatics, King's College London, London, UK. alfredo.iacoangeli@kcl.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Maudsley Biomedical Research Centre (BRC) at South London and Maudsley NHS Foundation Trust and King's College London, London, UK. alfredo.iacoangeli@kcl.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Chalabi</LastName><ForeName>Ammar</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4924-7712</Identifier><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, London, SE5 9RX, UK. ammar.al-chalabi@kcl.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>King's College Hospital, Bessemer Road, London, SE5 9RS, UK. ammar.al-chalabi@kcl.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/R024804/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>ALCHALABI-TALBOT/APR14/926-794</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>ALCHALABI-DOBSON/APR14/829-791</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L501529/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Genome Med</MedlineTA><NlmUniqueID>101475844</NlmUniqueID><ISSNLinking>1756-994X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019683" MajorTopicYN="N">Penetrance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010375" MajorTopicYN="N">Pedigree</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005191" MajorTopicYN="N">Family Characteristics</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Autosomal dominant</Keyword><Keyword MajorTopicYN="N">Disease</Keyword><Keyword MajorTopicYN="N">Familial</Keyword><Keyword MajorTopicYN="N">Penetrance</Keyword><Keyword MajorTopicYN="N">Sporadic</Keyword><Keyword MajorTopicYN="N">Variant</Keyword></KeywordList><CoiStatement>CML sits on the SAB for Myriad Neuroscience. AAC reports consultancies or advisory boards for Amylyx, Apellis, Biogen Idec, Brainstorm, Cytokinetics, GSK, Lilly, Mitsubishi Tanabe Pharma, Novartis, OrionPharma, Quralis, and Wave Pharmaceuticals. The remaining authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>15</Day><Hour>23</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36522764</ArticleId><ArticleId IdType="pmc">PMC9753373</ArticleId><ArticleId IdType="doi">10.1186/s13073-022-01142-7</ArticleId><ArticleId IdType="pii">10.1186/s13073-022-01142-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet. 2004;65(4):267&#x2013;277. doi: 10.1111/j.1399-0004.2004.00241.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-0004.2004.00241.x</ArticleId><ArticleId IdType="pubmed">15025718</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldwurm S, Tunesi S, Tesei S, et al. Kin-cohort analysis of LRRK2-G2019S penetrance in Parkinson's disease. Mov Disord. 2011;26(11):2144&#x2013;2145. doi: 10.1002/mds.23807.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.23807</ArticleId><ArticleId IdType="pubmed">21714003</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewey FE, Grove ME, Pan C, et al. Clinical Interpretation and Implications of Whole-Genome Sequencing. JAMA. 2014;311(10):1035&#x2013;1045. doi: 10.1001/jama.2014.1717.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2014.1717</ArticleId><ArticleId IdType="pmc">PMC4119063</ArticleId><ArticleId IdType="pubmed">24618965</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalia SS, Adelman K, Bale SJ, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet Med. 2017;19(2):249&#x2013;55. doi: 10.1038/gim.2016.190.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gim.2016.190</ArticleId><ArticleId IdType="pubmed">27854360</ArticleId></ArticleIdList></Reference><Reference><Citation>Saelaert M, Mertes H, Moerenhout T, De Baere E, Devisch I. Criteria for reporting incidental findings in clinical exome sequencing &#x2013; a focus group study on professional practices and perspectives in Belgian genetic centres. BMC Med Genomics. 2019;12(1):123. doi: 10.1186/s12920-019-0561-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12920-019-0561-0</ArticleId><ArticleId IdType="pmc">PMC6702726</ArticleId><ArticleId IdType="pubmed">31429751</ArticleId></ArticleIdList></Reference><Reference><Citation>Senol-Cosar O, Schmidt RJ, Qian E, et al. Considerations for clinical curation, classification, and reporting of low-penetrance and low effect size variants associated with disease risk. Genet Med. 2019;21(12):2765&#x2013;2773. doi: 10.1038/s41436-019-0560-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41436-019-0560-8</ArticleId><ArticleId IdType="pubmed">31147632</ArticleId></ArticleIdList></Reference><Reference><Citation>Otto PA, Horimoto ARVR. Penetrance rate estimation in autosomal dominant conditions. Genet Mol Biol. 2012;35(3):583&#x2013;588. doi: 10.1590/S1415-47572012005000051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/S1415-47572012005000051</ArticleId><ArticleId IdType="pmc">PMC3459406</ArticleId><ArticleId IdType="pubmed">23055795</ArticleId></ArticleIdList></Reference><Reference><Citation>Minikel EV, Vallabh SM, Lek M, et al. Quantifying prion disease penetrance using large population control cohorts. Sci Transl Med. 2016;8(322):322ra9. doi: 10.1126/scitranslmed.aad5169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aad5169</ArticleId><ArticleId IdType="pmc">PMC4774245</ArticleId><ArticleId IdType="pubmed">26791950</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright CF, West B, Tuke M, et al. Assessing the Pathogenicity, Penetrance, and Expressivity of Putative Disease-Causing Variants in a Population Setting. Am J Hum Genet. 2019;104(2):275&#x2013;286. doi: 10.1016/j.ajhg.2018.12.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2018.12.015</ArticleId><ArticleId IdType="pmc">PMC6369448</ArticleId><ArticleId IdType="pubmed">30665703</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Battistini S, Calvo A, et al. Genetic counselling in ALS: facts, uncertainties and clinical suggestions. J Neurol Neurosurg Psychiatry. 2014;85(5):478. doi: 10.1136/jnnp-2013-305546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2013-305546</ArticleId><ArticleId IdType="pubmed">23833266</ArticleId></ArticleIdList></Reference><Reference><Citation>Shatunov A, Al-Chalabi A. The genetic architecture of ALS. Neurobiol Dis. 2021;147:105156. doi: 10.1016/j.nbd.2020.105156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2020.105156</ArticleId><ArticleId IdType="pubmed">33130222</ArticleId></ArticleIdList></Reference><Reference><Citation>Iacoangeli A, Al Khleifat A, Jones AR, et al. C9orf72 intermediate expansions of 24&#x2013;30 repeats are associated with ALS. Acta Neuropathol Commun. 2019;7:115. doi: 10.1186/s40478-019-0724-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-019-0724-4</ArticleId><ArticleId IdType="pmc">PMC6637621</ArticleId><ArticleId IdType="pubmed">31315673</ArticleId></ArticleIdList></Reference><Reference><Citation>Iacoangeli A, Al Khleifat A, Sproviero W, et al. ALSgeneScanner: a pipeline for the analysis and interpretation of DNA sequencing data of ALS patients. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:207&#x2013;215. doi: 10.1080/21678421.2018.1562553.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1562553</ArticleId><ArticleId IdType="pmc">PMC6567555</ArticleId><ArticleId IdType="pubmed">30835568</ArticleId></ArticleIdList></Reference><Reference><Citation>Abel O, Powell JF, Andersen PM, Al-Chalabi A. ALSoD: A user-friendly online bioinformatics tool for amyotrophic lateral sclerosis genetics. Hum Mutat. 2012;33(9):1345&#x2013;1351. doi: 10.1002/humu.22157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.22157</ArticleId><ArticleId IdType="pubmed">22753137</ArticleId></ArticleIdList></Reference><Reference><Citation>Opie-Martin S, Iacoangeli A, Topp SD, et al. The SOD1-mediated ALS phenotype shows a decoupling between age of symptom onset and disease duration. Nat Commun. 2022;13(1):6901. doi: 10.1038/s41467-022-34620-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-34620-y</ArticleId><ArticleId IdType="pmc">PMC9653399</ArticleId><ArticleId IdType="pubmed">36371497</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Lewis CM. Modelling the Effects of Penetrance and Family Size on Rates of Sporadic and Familial Disease. Hum Hered. 2011;71(4):281&#x2013;288. doi: 10.1159/000330167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000330167</ArticleId><ArticleId IdType="pubmed">21846995</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans JDW, Girerd B, Montani D, et al. BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. Lancet Respir Med. 2016;4(2):129&#x2013;137. doi: 10.1016/S2213-2600(15)00544-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(15)00544-5</ArticleId><ArticleId IdType="pmc">PMC4737700</ArticleId><ArticleId IdType="pubmed">26795434</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunink MGM, Weinstein MC, Wittenberg E, et al. Decision Making in Health and Medicine: Integrating Evidence and Values. 2. Cambridge: Cambridge University Press; 2014.</Citation></Reference><Reference><Citation>Spargo TP, Opie-Martin S, Bowles H, Lewis CM, Iacoangeli A, Al-Chalabi A. ADPenetrance. 2022. GitHub. Available from: https://github.com/ThomasPSpargo/adpenetrance.</Citation></Reference><Reference><Citation>Spargo TP, Opie-Martin S, Bowles H, Lewis CM, Iacoangeli A, Al-Chalabi A. ADPenetrance: penetrance estimation for autosomal dominant traits. 2022. Available from: https://adpenetrance.rosalind.kcl.ac.uk/.</Citation></Reference><Reference><Citation>Chang W, Cheng J, Allaire J, et al. shiny: Web Application Framework for R. 2022. R package version 1.7.3. Available from: https://CRAN.R-project.org/package=shiny.</Citation></Reference><Reference><Citation>Fertility rate, total (births per woman) [Internet]. 2020. Available from: https://databank.worldbank.org/reports.aspx?source=2&amp;series=SP.DYN.TFRT.IN. Accessed 12 Jan 2021.</Citation></Reference><Reference><Citation>Shino MY, McGuire V, Van Den Eeden SK, et al. Familial aggregation of Parkinson's disease in a multiethnic community-based case-control study. Mov Disord. 2010;25(15):2587&#x2013;2594. doi: 10.1002/mds.23361.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.23361</ArticleId><ArticleId IdType="pmc">PMC2978761</ArticleId><ArticleId IdType="pubmed">20842689</ArticleId></ArticleIdList></Reference><Reference><Citation>Elbaz A, Grigoletto F, Baldereschi M, et al. Familial aggregation of Parkinson&#x2019;s disease. Neurology. 1999;52(9):1876. doi: 10.1212/WNL.52.9.1876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.52.9.1876</ArticleId><ArticleId IdType="pubmed">10371537</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkinson&#x2019;s UK. The Incidence and Prevalence of Parkinson&#x2019;s in the UK: Results from the Clinical Practice Research Datalink Reference Report. 2017. Available from: https://www.parkinsons.org.uk/professionals/resources/incidence-and-prevalence-parkinsons-uk-report.</Citation></Reference><Reference><Citation>Healy DG, Falchi M, O'Sullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol. 2008;7(7):583&#x2013;590. doi: 10.1016/S1474-4422(08)70117-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(08)70117-0</ArticleId><ArticleId IdType="pmc">PMC2832754</ArticleId><ArticleId IdType="pubmed">18539534</ArticleId></ArticleIdList></Reference><Reference><Citation>Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581(7809):434&#x2013;443. doi: 10.1038/s41586-020-2308-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2308-7</ArticleId><ArticleId IdType="pmc">PMC7334197</ArticleId><ArticleId IdType="pubmed">32461654</ArticleId></ArticleIdList></Reference><Reference><Citation>Thenappan T, Ryan JJ, Archer SL. Evolving epidemiology of pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012;186(8):707&#x2013;709. doi: 10.1164/rccm.201207-1266ED.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201207-1266ED</ArticleId><ArticleId IdType="pmc">PMC3480514</ArticleId><ArticleId IdType="pubmed">23071187</ArticleId></ArticleIdList></Reference><Reference><Citation>Corris PA, Seeger W. Call it by the correct name&#x2014;pulmonary hypertension not pulmonary arterial hypertension: growing recognition of the global health impact for a well-recognized condition and the role of the Pulmonary Vascular Research Institute. Am J Physiol Lung Cell Mol. 2020;318(5):L992&#x2013;L994. doi: 10.1152/ajplung.00098.2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.00098.2020</ArticleId><ArticleId IdType="pubmed">32233785</ArticleId></ArticleIdList></Reference><Reference><Citation>Aldred MA, Vijayakrishnan J, James V, et al. BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension. Hum Mutat. 2006;27(2):212&#x2013;213. doi: 10.1002/humu.9398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.9398</ArticleId><ArticleId IdType="pubmed">16429403</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne S, Walsh C, Lynch C, et al. Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2011;82(6):623&#x2013;627. doi: 10.1136/jnnp.2010.224501.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2010.224501</ArticleId><ArticleId IdType="pubmed">21047878</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne S, Heverin M, Elamin M, et al. Aggregation of neurologic and neuropsychiatric disease in amyotrophic lateral sclerosis kindreds: A population-based case&#x2013;control cohort study of familial and sporadic amyotrophic lateral sclerosis. Ann Neurol. 2013;74(5):699&#x2013;708. doi: 10.1002/ana.23969.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23969</ArticleId><ArticleId IdType="pubmed">23836460</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso A, Logroscino G, Jick SS, Hern&#xe1;n MA. Incidence and lifetime risk of motor neuron disease in the United Kingdom: a population-based study. Eur J Neurol. 2009;16(6):745&#x2013;751. doi: 10.1111/j.1468-1331.2009.02586.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2009.02586.x</ArticleId><ArticleId IdType="pmc">PMC3093130</ArticleId><ArticleId IdType="pubmed">19475756</ArticleId></ArticleIdList></Reference><Reference><Citation>Marogianni C, Rikos D, Provatas A, et al. The role of C9orf72 in neurodegenerative disorders: a systematic review, an updated meta-analysis, and the creation of an online database. Neurobiol Aging. 2019;84:1.e&#x2013;e10. doi: 10.1016/j.neurobiolaging.2019.04.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2019.04.012</ArticleId><ArticleId IdType="pubmed">31126629</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou Z-Y, Zhou Z-R, Che C-H, Liu C-Y, He R-L, Huang H-P. Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2017;88:540&#x2013;549. doi: 10.1136/jnnp-2016-315018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2016-315018</ArticleId><ArticleId IdType="pubmed">28057713</ArticleId></ArticleIdList></Reference><Reference><Citation>Larkin EK, Newman JH, Austin ED, et al. Longitudinal Analysis Casts Doubt on the Presence of Genetic Anticipation in Heritable Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2012;186(9):892&#x2013;896. doi: 10.1164/rccm.201205-0886OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201205-0886OC</ArticleId><ArticleId IdType="pmc">PMC3530218</ArticleId><ArticleId IdType="pubmed">22923661</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen PM. Amyotrophic lateral sclerosis associated with mutations in the CuZn superoxide dismutase gene. Curr Neurol Neurosci Rep. 2006;6(1):37&#x2013;46. doi: 10.1007/s11910-996-0008-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11910-996-0008-9</ArticleId><ArticleId IdType="pubmed">16469270</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, McKenna-Yasek D, Sapp PE, et al. Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis. Ann Neurol. 1997;41(2):210&#x2013;221. doi: 10.1002/ana.410410212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410410212</ArticleId><ArticleId IdType="pubmed">9029070</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M, van Es MA, Hennekam EAM, et al. Evidence for an oligogenic basis of amyotrophic lateral sclerosis. Hum Mol Genet. 2012;21(17):3776&#x2013;3784. doi: 10.1093/hmg/dds199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/dds199</ArticleId><ArticleId IdType="pubmed">22645277</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck J, Poulter M, Hensman D, et al. Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population. Am J Hum Genet. 2013;92(3):345&#x2013;353. doi: 10.1016/j.ajhg.2013.01.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2013.01.011</ArticleId><ArticleId IdType="pmc">PMC3591848</ArticleId><ArticleId IdType="pubmed">23434116</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy NA, Arthur KC, Tienari PJ, Houlden H, Chio A, Traynor BJ. Age-related penetrance of the C9orf72 repeat expansion. Sci Rep. 2017;7(1):2116. doi: 10.1038/s41598-017-02364-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-02364-1</ArticleId><ArticleId IdType="pmc">PMC5437033</ArticleId><ArticleId IdType="pubmed">28522837</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyle-Gilchrist ITS, Dick KM, Patterson K, et al. Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes. Neurology. 2016;86(18):1736. doi: 10.1212/WNL.0000000000002638.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002638</ArticleId><ArticleId IdType="pmc">PMC4854589</ArticleId><ArticleId IdType="pubmed">27037234</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Al-Chalabi A, Chio A, et al. Genetic screening in sporadic ALS and FTD. J Neurol Neurosurg Psychiatry. 2017;88(12):1042&#x2013;1044. doi: 10.1136/jnnp-2017-315995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-315995</ArticleId><ArticleId IdType="pmc">PMC5740553</ArticleId><ArticleId IdType="pubmed">28642287</ArticleId></ArticleIdList></Reference><Reference><Citation>Majounie E, Renton AE, Mok K, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 2012;11(4):323&#x2013;330. doi: 10.1016/s1474-4422(12)70043-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1474-4422(12)70043-1</ArticleId><ArticleId IdType="pmc">PMC3322422</ArticleId><ArticleId IdType="pubmed">22406228</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Mazzini L, Alfonso S, et al. The multistep hypothesis of ALS revisited. Neurology. 2018;91(7):e635. doi: 10.1212/WNL.0000000000005996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000005996</ArticleId><ArticleId IdType="pmc">PMC6105040</ArticleId><ArticleId IdType="pubmed">30045958</ArticleId></ArticleIdList></Reference><Reference><Citation>Vajda A, McLaughlin RL, Heverin M, et al. Genetic testing in ALS: A survey of current practices. Neurol. 2017;88(10):991&#x2013;999. doi: 10.1212/wnl.0000000000003686.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.0000000000003686</ArticleId><ArticleId IdType="pmc">PMC5333513</ArticleId><ArticleId IdType="pubmed">28159885</ArticleId></ArticleIdList></Reference><Reference><Citation>King&#x2019;s College London. King's Computational Research, Engineering and Technology Environment (CREATE) 2022 [October 12 2022]. Available from: 10.18742/rnvf-m076.</Citation></Reference><Reference><Citation>Hughes I, Hase T. Measurements and their uncertainties: a practical guide to modern error analysis. Oxford: Oxford University Press; 2010.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>